- Home
- SNTI vs CUE Comparison
SNTI vs CUE Comparison
Compare SNTI & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CUE
- Stock Information
- Founded
- SNTI 2016
- CUE 2014
- Country
- SNTI United States
- CUE United States
- Employees
- SNTI N/A
- CUE N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- CUE Health Care
- Exchange
- SNTI Nasdaq
- CUE Nasdaq
- Market Cap
- SNTI 53.6M
- CUE 61.1M
- IPO Year
- SNTI N/A
- CUE 2018
- Fundamental
- Price
- SNTI $2.15
- CUE $0.70
- Analyst Decision
- SNTI Strong Buy
- CUE Strong Buy
- Analyst Count
- SNTI 3
- CUE 2
- Target Price
- SNTI $9.67
- CUE $3.00
- AVG Volume (30 Days)
- SNTI 327.7K
- CUE 267.2K
- Earning Date
- SNTI 11-13-2025
- CUE 11-13-2025
- Dividend Yield
- SNTI N/A
- CUE N/A
- EPS Growth
- SNTI N/A
- CUE N/A
- EPS
- SNTI N/A
- CUE N/A
- Revenue
- SNTI N/A
- CUE $8,286,000.00
- Revenue This Year
- SNTI N/A
- CUE N/A
- Revenue Next Year
- SNTI $150.00
- CUE N/A
- P/E Ratio
- SNTI N/A
- CUE N/A
- Revenue Growth
- SNTI N/A
- CUE N/A
- 52 Week Low
- SNTI $1.26
- CUE $0.54
- 52 Week High
- SNTI $16.94
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- SNTI 62.17
- CUE 39.09
- Support Level
- SNTI $1.92
- CUE $0.69
- Resistance Level
- SNTI $2.29
- CUE $0.81
- Average True Range (ATR)
- SNTI 0.25
- CUE 0.04
- MACD
- SNTI 0.01
- CUE -0.01
- Stochastic Oscillator
- SNTI 55.06
- CUE 6.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.